Agenus Inc. (AGEN)

Market Cap	298.60M
Revenue (ttm)	100.90M
Net Income (ttm)	-270.78M
Shares Out	381.50M
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,594,758
Open	0.785
Previous Close	0.777
Day's Range	0.740 - 0.800
52-Week Range	0.610 - 3.013
Beta	1.42
Analysts	Strong Buy
Price Target	8.12 (+937.44%)
Earnings Date	Nov 7, 2023

About AGEN

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-C...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2000
• Employees: 533
• Stock Exchange: NASDAQ
• Ticker Symbol: AGEN

Financial Performance

In 2022, Agenus's revenue was $98.02 million, a decrease of -66.85% compared to the previous year's $295.67 million. Losses were -$220.29 million, 812.6% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price forecast is $8.12, which is an increase of 937.44% from the latest price.

Price Target

$8.12

(937.44% upside)

Analyst Consensus: Strong Buy